According to the sources provided, there is limited information on the safety of Cosentyx (secukinumab) during breastfeeding. The drug is classified as a pregnancy category B drug, which means that animal studies have not shown any adverse effects on the fetus, but there are no adequate and well-controlled studies in pregnant women [3]. It is also not known whether Cosentyx is excreted in human milk, and the potential risks to the nursing infant are unknown [2].

The prescribing information for Cosentyx states that the drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus [2]. The same caution should be exercised when considering the use of Cosentyx in breastfeeding women [2].

It is recommended that healthcare providers discuss the potential risks and benefits of Cosentyx with their patients who are pregnant or breastfeeding before prescribing the drug [3]. They should also monitor the infants of breastfeeding women who are taking Cosentyx for any adverse effects [2].

In summary, while there is limited information on the safety of Cosentyx during breastfeeding, healthcare providers should exercise caution when considering the use of the drug in breastfeeding women. The potential risks and benefits should be discussed with the patient, and infants should be monitored for any adverse effects.

Sources:
[2] Cosentyx Prescribing Information. Novartis Pharmaceuticals Corporation. Retrieved from https://www.cosentyx.com/pdf/cosentyx-prescribing-information.pdf
[3] DrugPatentWatch. Cosentyx. Retrieved from https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[4] National Center for Biotechnology Information. StatPearls [Internet]. Bethesda (MD): National Library of Medicine (US), 2021. Secukinumab. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK537091/